Pharma Journalist -

Celgene Corporation and Juno Therapeutics signed a definitive merger agreement in which Celgene has initiated acquisition of Juno Therapeutics. As per the terms of the agreement, …
Read More...

Seattle Genetics confirmed that its collaborator, Takeda Pharmaceutical Company Limited has asserted the fact that European Commission has extended the current conditional marketing…
Read More...

In order to offer a robust, and economically viable solution for anatomical pathology, Enzo Biochem asserted the authentication of a cervical Cancer biomarker detection test offering a…
Read More...

Baxter asserted the approval of U.S. Food and Drug Administration for Bivalirudin in 0.9 percent Sodium Chloride Injection (bivalirudin). Baxter's premixed medications are manufactured…
Read More...

U.S FDA has granted 510 (k) clearance to Bio-Rad Laboratories for the IH-Incubator L and IH-Centrifuge L instruments to be used with the full range of Bio-Rad’s IH-System Gel Reagents…
Read More...

Enzychem Lifesciences Corp asserted that the US Food and Drug Administration has granted Orphan Drug Designation to EC-18 for treating Acute Radiation Syndrome. US FDA Orphan Drug…
Read More...

Astellas Pharma and Vical asserted the negative results for Phase 3 Helios Clinical Trial for ASP0113, an investigational DNA vaccine being developed for cytomegalovirus…
Read More...

Boston-based Biopharmaceutical company, BERG proclaimed that the U.SS FDA has extended orphan-drug designation to the Company's leading product candidate BPM31510, for the treatment of…
Read More...

Immuno-oncology company, Agenus asserted the launch of its proprietary anti- CTLA4 (AGEN1884) and anti-PD1 (AGEN2034) antibodies. The open-label Phase 1/2 study is designed to evaluate…
Read More...

Clinical stage Biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, Pulmatrix sought approval of its Clinical Trial Application from…
Read More...